Osteoclast‐derived complement component 3a stimulates osteoblast differentiation

K Matsuoka, K Park, M Ito, K Ikeda… - Journal of Bone and …, 2014 - academic.oup.com
K Matsuoka, K Park, M Ito, K Ikeda, S Takeshita
Journal of Bone and Mineral Research, 2014academic.oup.com
Bone remodeling is regulated by a coupling of resorption to subsequent formation; however,
the “coupling factor” and underlying mechanism are not fully understood. Here, we found
that the condition medium (CM) of mature osteoclasts contains a humoral factor that
stimulates the differentiation of primary osteoblasts, as determined by alkaline phosphatase
(ALP) activity. We purified osteoblastogenesis‐stimulating activity from 3 L of osteoclast CM
through successive ion exchange chromatographies by monitoring the ALP activity of …
Abstract
Bone remodeling is regulated by a coupling of resorption to subsequent formation; however, the “coupling factor” and underlying mechanism are not fully understood. Here, we found that the condition medium (CM) of mature osteoclasts contains a humoral factor that stimulates the differentiation of primary osteoblasts, as determined by alkaline phosphatase (ALP) activity. We purified osteoblastogenesis‐stimulating activity from 3 L of osteoclast CM through successive ion exchange chromatographies by monitoring the ALP activity of osteoblasts and identified complement component 3 (C3). Expression of the C3 gene increased during osteoclastogenesis, and the cleavage product C3a was detected by ELISA in the CM of osteoclasts but not in that of bone marrow macrophages. The osteoblastogenesis‐stimulating activity present in osteoclast CM was inhibited by a specific antagonist of the C3a receptor (C3aR), SB290157. Conversely, the retroviral expression of C3a as well as treatment with the C3aR agonist, benzeneacetamide, stimulated osteoblast differentiation. C3 gene expression in bone was increased in the high bone turnover states of ovariectomy (OVX) or a receptor activator of NF‐κB ligand (RANKL) injection, and blocking the action of C3a with the daily administration of SB290157 resulted in the attenuation of bone formation elevated by OVX and the exacerbation of bone loss. These results suggest that osteoclast‐derived C3a functions in the relay from bone resorption to formation and may be a candidate for a coupling factor. © 2014 American Society for Bone and Mineral Research.
Oxford University Press